Want to see ABBV full AI Analyst Report?
Operating Expense Breakdown
Lists R&D, selling & marketing, and administrative costs so you can see how AbbVie balances spending on new drugs versus commercial efforts and overhead. Shifts in these buckets signal priorities — more R&D points to pipeline investment, rising SG&A can reflect heavy marketing of new launches, and efficiency gains matter for future margins and free cash flow.AbbVie’s expense profile shows rising core R&D investment and relatively disciplined SG&A, but large, lumpy acquired IPR&D charges drive quarter‑to‑quarter volatility and can meaningfully depress reported margins. Management explicitly excludes future IPR&D from guidance, signaling these are treated as strategic, nonrecurring bets to accelerate the pipeline—supporting Skyrizi/Rinvoq and new neuroscience/obesity programs—but investors should focus on the underlying R&D run‑rate and adjusted margins rather than headline swings caused by acquisition-related charges.
Date | Research and Development | Selling, General, and Administrative | Other | Acquired In-Process R&D |
|---|---|---|---|---|
Jun 30, 2026 | $2.34B | $3.63B | $0.00 | $291.00M |
Mar 31, 2026 | $2.47B | $3.58B | $0.00 | $744.00M |
Dec 31, 2025 | $2.58B | $3.90B | -$217.00M | $1.26B |
Sep 30, 2025 | $2.32B | $3.57B | $0.00 | $2.68B |
Jun 30, 2025 | $2.13B | $3.25B | -$24.00M | $823.00M |
Mar 31, 2025 | $2.07B | $3.29B | $0.00 | $248.00M |
Dec 31, 2024 | $6.77B | $3.85B | -$7.00M | $1.57B |
Sep 30, 2024 | $2.13B | $4.21B | $0.00 | $82.00M |
Jun 30, 2024 | $1.95B | $3.38B | $0.00 | $937.00M |
Mar 31, 2024 | $1.94B | $3.31B | $0.00 | $164.00M |